# Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

> **NCT03212807** · PHASE2 · WITHDRAWN · sponsor: **Singapore General Hospital**

## Conditions studied

- EBV Related Non-Hodgkin's Lymphoma
- Primary CNS Lymphoma
- Primary Testicular Lymphoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03212807
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08
- **Primary completion:** 2021-02
- **Final completion:** 2023-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212807, "Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03212807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*